Grooving (and a-Vexed?) and breaking news!

October 8, 2009 By Paul Dalton

CC is a horse, Jeter is a stud, A Rod has chased away his ghosts, and the Yankees lead the series 1-0.

Avexa, the company developing apriciabine, released a cryptic (a-vexing?) press release saying that the study, meant to be 48 weeks, was being closed early in order to 'offer key insight into ATC's role in the overall HIV treatment landscape, and discussions with regulatory authorities may clarify the ATC approval path. Secondly, this will allow for a mature enough data point to enable potential partners the ability to make a definitive decision on licensing of ATC.

The Avexa press release, while not really telling us anything, suggests to me that this drug is dead in the water. Typically when companies have positive news they share it. This is even more true of smaller companies, who are dependent on investors.

© 2026 Smart + Strong All Rights Reserved.